Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eVOLVE-01: Volrustomig priming regimen in solid tumors
CTR20243284Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of volrustomig in Non-small cell lung cancer (NS-NSCLC), non-squamous non-small cell lung cancer, sponsored by AstraZeneca. Started Dec 2024; status: active.
02
Drugs
volrustomig
03
Conditions
Non-small cell lung cancer (NS-NSCLC)non-squamous non-small cell lung cancer
Beyond the preview
Go deeper on CTR20243284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243284.